Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

NCT05587309 is registered in ClinicalTrials.gov with Braintree Laboratories as lead sponsor.

NCT NCT05587309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05587309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
Lead sponsor
Braintree Laboratories
Phase
Phase 3
Overall status
Completed
Start date
October 30, 2022
Completion date
June 16, 2025
Enrollment
1,250 (actual)
Sites
122

Conditions

As the registry lists them; a condition with its own page is linked.

erosive esophagitis